{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.49","upperLimit":"13.95","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"description":"Percentage of participants who achieved biochemical control defined as GH \\<1μg/L and IGF-1 \\<ULN at week 36, for participants who had been up-titrated with pasireotide LAR 60 mg.","dispersionType":"95% Confidence Interval","groups":[{"description":"This is the subset of participants in the FAS who started treatment with 40 mg pasireotide LAR in the core phase and were up-titrated to pasireotide LAR 60 mg.","id":"OG000","title":"Up-titrated to Pasireotide LAR 60 mg"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study. For these patients the Pasireotide LAR dose was uptitrated to 60 mg before Week 36.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 for Participants Up-titrated to Pasireotide LAR 60 mg","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}